Novel immune modulators used in hematology: Impact on NK cells

Frontiers in Immunology

Volumn 3, Issue JAN, 2012, Pages

  Krieg, Stephanie ^a   Ullrich, Evelyn ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

bortezomib; Glivec ; HDACi; Imid ; Lenalidomide; NK cell; Thalidomide; TKi

Indexed keywords

EID: 84874296249     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00388     Document Type: Review

References (90)

1. Ali, S., Sergeant, R., O'Brien, S. G., Foroni, L., Hedgley, C., Ger-rard, G., et al. (2012). Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia. Blood 120, 697-698.
2. Alvarez-Breckenridge, C. A., Yu, J., Price, R., Wei, M., Wang, Y., Nowicki, M. O., et al. (2012). The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon. J. Virol. 86, 4566-4577.
3. Ames, E., Hallett, W H., and Murphy, W J. (2009). Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition. Clin. Exp. Immunol. 155, 504-513.
4. Anshelevich, A., Wysocka, M., Benoit, B. M., and Rook, A. H. (2010). "Minimizing the immuno-suppressive effects of histone deacetylase inhibitors (HDACi): implications for therapy of cutaneous T-cell lymphoma (CTCL)," in First World Congress of Cutaneous Lymphomas, September 22-25, Chicago, IL.
5. Armeanu, S., Bitzer, M., Lauer, U. M., Venturelli, S., Pathil, A., Krusch, M., et al. (2005). Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 65, 6321-6329.
6. Balachandran, V. P., Cavnar, M. J., Zeng, S., Bamboat, Z. M., Ocuin, L. M., Obaid, H., et al. (2011). Ima-tinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat.Med. 17, 1094-1100.
7. Baron, F., Turhan, A. G., Giron-Michel, J., Azzarone, B., Bentires-Alj, M., Bours, V., et al. (2002). Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. Blood 99, 2107-2113.
8. Bartlett, J. B., Dredge, K., and Dal-gleish, A. G. (2004a). The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer 4, 314-322.
9. Bartlett, J. B., Michael, A., Clarke, I. A., Dredge, K., Nicholson, S., Kris-teleit, H., et al. (2004b). Phase I study to determine the safety, tolera-bility and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br. J. Cancer 90, 955-961.
10. Bennasroune, A., Gardin, A., Aunis, D., Crémel, G., and Hubert, P. (2004). Tyrosine kinase receptors as attractive targets of cancer therapy. Crit. Rev. Oncol. Hematol. 50, 23-38.
11. Blake, S. J., Bruce Lyons, A., Fraser, C. K., Hayball, J. D., and Hughes, T. P. (2008). Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood 111, 4415-4416.
12. Boissel, N., Rea, D., Tieng, V., Dulphy, N., Brun, M., Cayuela, J. M., et al. (2006). BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J. Immunol. 176, 5108-5116.
13. Borg, C., Terme, M., Taïeb, J., Ménard, C., Flament, C., Robert, C., et al. (2004). Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest. 114, 379-388.
14. Butler, J. E., Moore, M. B., Presnell, S. R., Chan, H. W., Chalupny, N. J., and Lutz, C. T. (2009). Proteasome regulation of ULBP1 transcription. J. Immunol. 182, 6600-6609.
15. Cebo, C., Da Rocha, S., Wittnebel, S., Turhan, A. G., Abdelali, J., Caillat-Zucman, S., et al. (2006). The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation. J. Immunol. 176, 864-872.
16. Chan, H. W., Miller, J. S., Moore, M. B., and Lutz, C. T. (2005). Epige-netic control of highly homologous killer Ig-like receptor gene alleles. J. Immunol. 175, 5966-5974.
17. Chen, C. I., Koschmieder, S., Kerstiens, L., Schemionek, M., Altvater, B., Pscherer, S., et al. (2012). NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. Leukemia 26, 465-474.
18. Chen, J., Schmitt, A., Chen, B., Rojew-ski, M., Rübeler, V., Fei, F., et al. (2008). Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling. J. Cell. Mol. Med. 12, 2107-2118.
19. Christman, J. K. (2002). 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21, 5483-5495.
20. Dauguet, N., Fournie, J., Poupot, R., and Poupot, M. (2010). Lenalido-mide down regulates the production of interferon-gamma and the expression of inhibitory cytotoxic receptors of human natural killer cells. Cell. Immunol. 264, 163-170.
21. Davies, F. E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y. T., et al. (2001). Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98, 210-216.
22. Diermayr, S., Himmelreich, H., Durovic, B., Mathys-Schneeberger, A., Siegler, U., Langenkamp, U., et al. (2008). NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 111, 1428-1436.
23. Feng, X., Yan, J., Wang, Y., Zierath, J. R., Nordenskjöld, M., Henter, J. I., et al. (2010). The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells. Mol. Immunol. 47, 2388-2396.
24. Fraser, C. K., Blake, S. J., Diener, K. R., Lyons, A. B., Brown, M. P., Hughes, T. P., et al. (2009). Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp. Hematol. 37, 256-265.
25. Gao, X. N., Lin, J., Wang, L. L., and Yu, L. (2009). Demethylating treatment suppresses natural killer cell cytolytic activity. Mol. Immunol. 46, 2064-2070.
26. Garcia-Manero, G. (2008). Demethylating agents in myeloid malignancies. Curr. Opin. Oncol. 20, 705-710.
27. Gasser, S., Orsulic, S., Brown, E. J., and Raulet, D. H. (2005). The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436, 1186-1190.
28. Glozak, M. A., and Seto, E. (2007). Histone deacetylases and cancer. Oncogene 26, 5420-5432.
29. Gorgun, G., Calabrese, E., Soydan, E., Hideshima, T., Perrone, G., Bandi, M., et al. (2010). Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 116, 3227-3237.
30. Hallett, W H., Ames, E., Motarjemi, M., Barao, I., Shanker, A., Tamang, D. L., et al. (2008). Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J. Immunol. 180, 163-170.
31. Hassold, N., Seystahl, K., Kempf, K., Urlaub, D., Zekl, M., Einsele, H., et al. (2012). Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib. Int. J. Cancer 131, E916-E927.
32. Hayashi, T., Hideshima, T., Akiyama, M., Podar, K., Yasui, H., Raje, N., et al. (2005). Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br. J. Haematol. 128, 192-203.
33. Hernandez-Ilizaliturri, F. J., Reddy, N., Holkova, B., Ottman, E., and Czucz-man, M. S. (2005). Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin. Cancer Res. 11, 5984-5992.
34. Huang, Y., Wang, Y., Li, Y., Guo, K., and He, Y. (2011). Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2. J. Cancer Res. Clin. Oncol. 137, 829-837.
35. Issa, J. P., Kantarjian, H., and Kirk-patrick, P. (2005). Azacitidine. Nat. Rev. DrugDiscov. 4, 275-276.
36. Jardine, L., Hambleton, S., Bigley, V., Pagan, S., Wang, X. N., and Collin, M. (2012). Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands. Leuk. Lymphoma. doi: 10.3109/10428194.2012.708026 [Epub ahead of print].
37. Kato, N., Tanaka, J., Sugita, J., Toubai, T., Miura, Y., Ibata, M., et al. (2007). Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. Leukemia 21, 2103-2108.
38. Kelly-Sell, M. J., Kim, Y H., Straus, S., Benoit, B., Harrison, C., Sutherland, K., et al. (2012). The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients. Am. J. Hematol. 87, 354-360.
39. Khan, O., and La Thangue, N. B. (2012). HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol. Cell Biol. 90, 85-94.
40. Kim, D. H., Kamel-Reid, S., Chang, H., Sutherland, R., Jung, C. W., Kim, H. J., et al. (2009). Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haema-tologica94, 135-139.
41. Kohga, K., Takehara, T., Tatsumi, T., Ishida, H., Miyagi, T., Hosui, A., et al. (2010). Sorafenib inhibits the shedding of major histocompatibil-ity complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9. Hepatology 51, 1264-1273.
42. Kreutzman, A., Jaatinen, T., Greco, D., Vakkila, E., Richter, J., Ekblom, M., et al. (2012). Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia. Exp. Hematol. 40, 906-913.e1.
43. Kreutzman, A., Juvonen, V., Kairisto, V., Ekblom, M., Stenke, L., Seggewiss, R., et al. (2010). Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 116, 772-782.
44. Krusch, M., and Salih, H. R. (2011). Effects of BCR-ABL inhibitors on anti-tumor immunity. Curr. Med. Chem. 18,5174-5184.
45. Krusch, M., Salih, J., Schlicke, M., Baessler, T., Kampa, K. M., Mayer, E, et al. (2009). The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro.J. Immunol. 183, 8286-8294.
46. Lioznov, M., El-Cheikh, J. Jr., Hoffmann, F., Hildebrandt, Y., Ayuk, E, Wolschke, C., et al. (2010). Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells. Bone Marrow Transplant. 45, 349-353.
47. Lundqvist, A., Abrams, S. I., Schrump, D. S., Alvarez, G., Suffredini, D., Berg, M., et al. (2006). Borte-zomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res. 66, 7317-7325.
48. Lundqvist, A., Berg, M., Smith, A., and Childs, R. W. (2011). Borte-zomib treatment to potentiate the anti-tumor immunity of ex-vivo expanded adoptively infused autolo-gous natural killer cells. J. Cancer 2, 383-385.
49. Lundqvist, A., Su, S.,Rao, S., and Childs, R. (2010). Cutting edge: bortezomib-treated tumors sensitized to NK cell apoptosis paradoxically acquire resistance to antigen-specific T cells. J. Immunol. 184, 1139-1142.
50. Lundqvist, A., Yokoyama, H., Smith, A., Berg, M., and Childs, R. (2009). Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood 113, 6120-6127.
51. Maggio, R., Peragine, N., De Propris, M. S., Vitale, A., Elia, L., Calabrese, E., et al. (2011). Immunocompetent cell functions in Ph+ acute lym-phoblastic leukemia patients on prolonged imatinib maintenance treatment. Cancer Immunol. Immunother. 60, 599-607.
52. Marin, D., Gabriel, I. H., Ahmad, S., Foroni, L., de Lavallade, H., Clark, R., et al. (2012). KIR2DS1 genotype predicts for complete cyto-genetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia 26, 296-302.
53. Marks, P. A., and Xu, W. S. (2009). His-tone deacetylase inhibitors: potential in cancer therapy. J. Cell. Biochem. 107, 600-608.
54. Menard, C., Blay, J. Y., Borg, C., Michiels, S., Ghiringhelli, F., Robert, C., et al. (2009). Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res. 69, 3563-3569.
55. Mustjoki, S., Ekblom, M., Dybedal, I., Epling-Burnette, P. K., Guilhot, E, et al. (2009). Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23, 1398-1405.
56. Ning, Z. Q., Li, Z. B., Newman, M. J., Shan, S., Wang, X. H., Pan, D. S., et al. (2012). Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benza-mide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother. Pharmacol. 69, 901-909.
57. Ogbomo, H., Michaelis, M., Kreuter, J., Doerr, H. W., and Cinatl, J. Jr. (2007). Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. FEBSLett. 581, 1317-1322.
58. Ohyashiki, K., Katagiri, S., Tauchi, T., Ohyashiki, J. H., Maeda, Y., Matsumura, I., et al. (2012). Increased natural killer cells and decreased CD3+ CD8+ CD62L+ T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib. Br. J. Haematol. 157, 254-256.
59. Orlowski, R. Z., and Kuhn, D. J. (2008). Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin. Cancer Res. 14, 1649-1657.
60. Payvandi, F., Wu, L., Naziruddin, S. D., Haley, M., Parton, A., Schafer, P. H., et al. (2005). Immunomodulatory drugs (IMiDs®) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT. J. Interferon Cytokine Res. 25, 604-616.
61. Pirrotta, M. T., Bernardeschi, P., and Fiorentini, G. (2011). Targeted-therapy in advanced renal cell carcinoma. Curr. Med. Chem. 18, 1651-1657.
62. Powles, T., Chowdhury, S., Bower, M., Saunders, N., Lim, L., Shamash, J., et al. (2011). The effect of sunitinib on immune subsets in metastatic clear cell renal cancer. Urol. Int. 86, 53-59.
63. Reddy, N., Hernandez-Ilizaliturri, E J., Deeb, G., Roth, M., Vaughn, M., Knight, J., et al. (2008). Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br. J. Haematol. 140, 36-45.
64. Rohner, A., Langenkamp, U., Siegler, U., Kalberer, C. P., and Wodnar-Filipowicz, A. (2007). Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leuk. Res. 31, 1393-1402.
65. Rossi, L. E., Avila, D. E., Spallan-zani, R. G., Ziblat, A., Fuertes, M, B., Lapyckyj, L., et al. (2012). Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression. J. Leukoc. Biol. 91, 321-331.
66. Salih, J., Hilpert, J., Placke, T., Grünebach, F., Steinle, A., Salih, H. R., et al. (2010). The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int. J. Cancer 127, 2119-2128.
67. Santourlidis, S., Trompeter, H. I., Wein-hold, S., Eisermann, B., Meyer, K. L., Wernet, P., et al. (2002). Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. J. Immunol. 169, 4253-4261.
68. Schade, A. E., Schieven, G. L., Townsend, R., Jankowska, A. M., Susulic, V., Zhang, R., et al. (2008). Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 111, 1366-1377.
69. Schmiedel, B. J., Arélin, V., Gruenebach, E, Krusch, M., Schmidt, S. M., Salih, H. R., et al. (2011). Azacyti-dine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation. Int. J. Cancer 128, 2911-2922.
70. Schmudde, M., Braun, A., Pende, D., Sonnemann, J., Klier, U., Beck, J. E, et al. (2008). Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. Cancer Lett. 272, 110-121.
71. Seggewiss, R., Loré, K., Greiner, E., Magnusson, M. K., Price, D. A., Douek, D. C., et al. (2005). Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 105, 2473-2479.
72. Shi, J., Tricot, G. J., Malaviarachchi, P. A., Szmania, S. M., Kellum, R. E., Storrie, B., et al. (2008). Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood 111, 1309-1317.
73. Skov, S., Pedersen, M. T., Andresen, L., Straten, P. T., Woetmann, A., Odum, N., et al. (2005). Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A andB. Cancer Res. 65, 11136-11145.
74. Soriani, A., Zingoni, A., Cerboni, C., Iannitto, M. L., Ricciardi, M. R., Di Gialleonardo, V., et al. (2009). ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 113, 3503-3511.
75. Stone, R., Sekeres, M., and Garcia-Manero, G. (2009). Evolving strategies in the treatment of MDS and AML. Clin. Adv. Hematol. Oncol. 7, 1-14.
76. Tai, Y T., Li, X. F., Catley, L., Coffey, R., Breitkreutz, I., Bae, J., et al. (2005). Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 65, 11712-11720.
77. Taieb, J., Chaput, N., Ménard, C., Apetoh, L., Ullrich, E., Bonmort, M., et al. (2006). A novel dendritic cell subset involved in tumor immuno-surveillance. Nat. Med. 12, 214-219.
78. Tanaka, H., Nakashima, S., and Usuda, M. (2012). Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients. Int. J. Hematol. 308-319.
79. Tang, K. F., He, C. X., Zeng, G. L., Wu, J., Song, G. B., Shi, Y, S., et al. (2008). Induction of MHC class I-related chain B (MICB) by 5-aza-2'-deoxycytidine. Biochem. Biophys. Res. Commun. 370, 578-583.
80. Tarek, N., Le Luduec, J. B., Gallagher, M. M., Zheng, J., Venstrom, J. M., Chamberlain, E., et al. (2012). Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J. Clin. Invest. 122, 3260-3270.
81. Terme, M., Ullrich, E., Delahaye, N. F., Chaput, N., and Zitvogel, L. (2008). Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat. Immunol. 9, 486-494.
82. Vales-Gomez, M., Chisholm, S. E., Cassady-Cain, R. L., Roda-Navarro, P., and Reyburn, H. T. (2008). Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors. Cancer Res. 68, 1546-1554.
83. Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., et al. (2011). Innate or adaptive immunity? The example of natural killer cells. Science 331, 44-49.
84. Voorhees, P. M., and Orlowski, R. Z. (2006). The proteasome and pro-teasome inhibitors in cancer therapy. Annu. Rev. Pharmacol Toxicol. 46, 189-213.
85. Wang, X., Ottosson, A., Ji, C., Feng, X., Nordenskjöld, M., Henter, J. I., et al. (2009). Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxic-ity. Haematologica 94, 470-478.
86. Weichsel, R., Dix, C., Wooldridge, L., Clement, M., Fenton-May, A., Sewell, A. K., et al. (2008). Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin. Cancer Res. 14, 2484-2491.
87. Wu, J. F., Zeng, G. L., Shen, W., Yang, M., Wang, F., Tian, L., et al. (2009). Up-regulation of major histocompatibility complex class I-related molecules A (MICA) induced by 5-aza-2'-deoxycytidine. Zhonghua Gan Zang Bing Za Zhi 17, 675-678.
88. Yong, A. S., Keyvanfar, K., Hensel, N., Eniafe, R., Savani, B. N., Berg, M., et al. (2009). Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood 113, 875-882.
89. Zhang, C., Wang, Y., Zhou, Z., Zhang, J., and Tian, Z. (2009). Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol Immunother. 58, 1275-1285.
90. Zhu, D., Corral, L. G., Fleming, Y W., and Stein, B. (2008). Immunomodu-latory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother. 57, 1849-1859.